Susceptibility of Escherichia coli against fosfomycin in urinary tract infections from people with disabilities who attended SENADIS. August 2021 to March 2022 and January to May 2023

Abstract

Background: Fosfomycin is a broad-spectrum antibiotic used for the treatment of lower urinary tract infections, it is active against gramnegative bacilli and grampositive cocci, as well as against multi-resistant microorganism, in addition to offering a therapeutic alternative for oral administration in a single dose, reaching an effectiveness of 90%. Aim: To study the susceptibility of Escherichia coli to fosfomycin in urinary tract infections, from isolated strains obtained from patients with disabilities. Methods: It is an observational, descriptive, prospective study in which a total of 273 urine culture samples of patients of both sexes who attended the SENADIS were included, and who at the time of the consultation presented symptoms of urinary tract infection. The urine positive cultures with significant bacterial growth were proceeded to determine its bacterial identification and the antibiogram according to CLSI recommendations. Results: Of these 273 samples, 91 samples were positive for different uropathogens, with 62/91 (68%) being positive for E. coli. Of these E. coli strains, 59/62 (95%) showed in vitro susceptibility to fosfomycin. Comment: Although the number of samples obtained is small and it cannot be extrapolated, we pretend to extend the work for a while longer to be able to compare it later. Conclusion: Fosfomycin has good activity in vitro against E. coli isolated from urine culture in our institution, representing a good alternative to be used in our study population